Efficacy of progesterone for moderate to severe traumatic brain injury: a meta-analysis of randomized clinical trials

Chao Lin1,*, Hongquan He2,*, Zheng Li1,*, Yinglong Liu1,*, Honglu Chao1, Jing Ji1 & Ning Liu1

Progesterone has been shown to have neuroprotective effects in multiple animal models of brain injury, whereas the efficacy and safety in patients with traumatic brain injury (TBI) remains contentious. Here, a total of seven randomized controlled trials (RCTs) with 2492 participants were included to perform this meta-analysis. Compared with placebo, there was no significant decrease to be found in the rate of death or vegetative state for patients with acute TBI (RR = 0.88, 95%CI = 0.70, 1.09, p = 0.24). Furthermore, progesterone was not associated with good recovery in comparison with placebo (RR = 1.00, 95%CI = 0.88, 1.14, p = 0.95). Together, our study suggested that progesterone did not improve outcomes over placebo in the treatment of acute TBI.

Traumatic brain injury (TBI) is a leading cause of death and disability and without effective treatment in children and young adults1–3. Despite improvement in outcome following brain injury in recent years, large numbers of patients remain disabled and dependent2,4. Previous animal studies suggested that progesterone could attenuate neural damage effectively by reducing free radicals, inflammatory cytokines, excitotoxicity, apoptosis, and vasogenic edema in the model of neurologic injury5–7. However, the relevant clinical trials of progesterone demonstrated different clinical benefits and discrepant conclusions for the treatment of patients with acute TBI8,9. Treatment recommendations may be misleading according to the results of any individual trial. Based on available data, we performed a meta-analysis of randomized clinical trials to compare progesterone with placebo for the treatment of patients with severe or moderate acute TBI. The overall evaluation was performed to accurately detail the efficacy and safety of progesterone.

Results

Study selection and characteristics. The detailed process of selection is shown in Fig. 1. In total, 295 potential studies were identified with a systematic search of databases. Seventy-five records were excluded as duplicates. We removed 209 apparently unsuitable articles including reviews, case reports and animal experiments after browsing titles and abstracts. The remaining studies were screened and assessed in detail by reviewing full texts. Four articles were excluded due to the following reasons: two excluded studies were not comparative trials, 1 study was an animal experiment, and 1 study involved comparison with another drug. Thus, 7 studies meeting our inclusion criteria were selected in this meta-analysis.

These seven studies, with 2492 total participants (Sample size, from 40 to 1179), compared progesterone with placebo in the treatment of acute TBI. Of these, only patients with severe TBI (Glasgow Coma Scale (GCS) ≤ 8) were included in five studies8–12, and in another 2 studies patients were recruited with
moderate-to-severe TBI (GCS $\leq 12$)\textsuperscript{13,14}. All female patients were excluded in one included study\textsuperscript{12}. The primary characteristics and quality assessments of the included RCTs are summarized in Table 1 and 2, respectively.

**Meta-analysis outcomes.** *Death or vegetative state.* The meta-analysis of seven RCTs with a random-effects model demonstrated that progesterone did not significantly reduce the rate of death or vegetative state in patients with acute TBI between the two groups (RR = 0.88, 95%CI = 0.70, 1.09, $p = 0.24$, $I^2 = 45\%$) (Fig. 2A). Subgroup meta-analysis was performed (Table 3). Due to the limited number of available studies, meta-regression was not pursued further. A similar result was observed in patients with severe TBI (RR = 0.86, 95%CI = 0.68, 1.09, $p = 0.20$, $I^2 = 48\%$) (Fig. 2B). The sensitivity analysis was performed to examine the influence of different models on the pooled estimates. There were

| Study/Year   | Trial design | No. of Patients | Age (y) | Male (%) | GCS on admission | Treatment                                                                 | Follow-up (M) |
|--------------|--------------|-----------------|---------|----------|------------------|---------------------------------------------------------------------------|---------------|
| Skolnick 2014 | RCT          | 1179            | 16 to 70| 927(78.63)| 4 to 8           | Intravenously 0.71 mg/kg for the first hour, then 0.50 mg/kg per hour for 119 hours | 6             |
| Shakeri 2013  | RCT          | 76              | 18 to 60| 76(100.00)| 3 to 8           | orally 1 mg/kg every 12 hours for 5 days                                   | 3             |
| Xiao 2008     | RCT          | 159             | 18 to 65| 115(72.33)| $\leq 8$          | intravenously 1.0 mg/kg every 12 hours for 5 days                        | 6             |
| Wright 2007   | RCT          | 100             | old than 18 | 71(71.00)| 4 to 12           | intravenously 0.71 mg/kg for the first hour, 0.5 mg/kg per hour for the next 11 hours, then 0.5 mg/kg per hour every 12 hours for 60 hours | 1             |
| Wright 2014   | RCT          | 882             | 17 to 94| 650(73.70)| 4 to 12           | intravenously 0.71 mg/kg for the first hour, then 0.5 mg/kg for 71 hours, then 0.125 mg/kg per hour every 8 hours for 96 hours | 6             |
| Xiao 2007     | RCT          | 56              | 15 to 65| 33(58.93)| 5 to 8           | Intramuscularly 80 mg every 12 hours for 5 days                           | 3             |
| Aminmansour 2012 | RCT      | 40              | 29.73*  | 28(70.00)| $\leq 8$          | Intramuscularly 1 mg/kg of progesterone every 12 hours for 5 days         | 3             |

Table 1. Basic characteristics of studies included in the meta-analysis. RCT, randomized controlled trial; GCS, Glasgow Coma Scale; Y, year; M, month; *mean age.
no significant changes to be found with a fixed-effects model (RR = 0.97, 95%CI = 0.84, 1.11, p = 0.65; RR = 0.95, 95%CI = 0.82, 1.10, p = 0.50).

**Good recovery.** In total, five of the included RCTs had an assessment of good recovery (GOS = 5) at the end of follow-up. No significant heterogeneity was observed in TBI (I² = 0%). Compared with placebo, the combined data using a fixed-effects model did not show that progesterone significantly increased the rate of good recovery (RR = 1.00, 95%CI = 0.88, 1.14, p = 0.95) (Fig. 3A). There was also no evidence to indicate that progesterone could improve the outcome for a good recovery in severe TBI (RR = 1.04, 95%CI = 0.91, 1.19, p = 0.54, I² = 0%) (Fig. 3B).

**Adverse events.** Two studies were included in the meta-analysis of adverse events. A fixed-effects model was used according to heterogeneity. There were no statistically significant differences in pneumonia or sepsis between the two groups (RR = 0.95, 95%CI = 0.85, 1.07, p = 0.42, I² = 0%; RR = 1.10, 95%CI = 0.76, 1.60, p = 0.61, I² = 0%) (Fig. 4).

**Publication bias.** There was no evidence of publication bias (Begg's test, P = 0.90; Egger's test, P = 0.059).

**Discussion**

The pathophysiology of acute TBI is a complex, interwoven and multifactorial process, which includes primary and secondary injury\(^{15,16}\). TBI-induced secondary injury has been considered to be a potential
target for therapeutic intervention involving reduction and prevention of inflammation, calcium flux, oxidative stress, necrosis, and apoptosis. Based on the efficacy and safety in animal models, progesterone has been regarded to be a potent candidate for the treatment of TBI. However, the relevant clinical trials of progesterone came to inconsistent conclusions. The previous review of progesterone for the treatment of TBI included only three small-scale and low-quality studies. In this current study, we selected 7 relevant RCTs including 2492 patients (progesterone: 1276 cases, placebo: 1216 cases) hospitalized for acute TBI to assess the efficacy of progesterone therapy on the Glasgow Outcome Scale (GOS) score and for adverse events.

Some previous clinical studies demonstrated that progesterone was a neuroprotective agent and improved outcomes for patients with acute severe TBI. However, we found no significant difference between the progesterone-treated group and the placebo group in the rate of death or vegetative state. Moreover, our results showed that progesterone was not associated with good recovery at the end of the follow-up period. To date, various drugs have been investigated in clinical trials, yet none has been

Table 3. Subgroup analysis for RCTs evaluating the efficacy in reducing death or vegetative state of patients with acute TBI. m, month; N, number of studies; CI: confidence interval; RR: risk ratios.

| Date of publication | N | RR  | 95% CI | Heterogeneity test (I²) |
|---------------------|---|-----|--------|------------------------|
| Before 2010         | 3 | 0.67| 0.47, 0.94 | 0%                     |
| After 2010          | 4 | 0.99| 0.80, 1.23 | 38%                    |

| Sample size         | N | RR  | 95% CI | Heterogeneity test (I²) |
|---------------------|---|-----|--------|------------------------|
| ≤ 100               | 4 | 0.70| 0.50, 0.96 | 0%                     |
| > 100               | 3 | 0.99| 0.77, 1.28 | 56%                    |

| Follow-up           | N | RR  | 95% CI | Heterogeneity test (I²) |
|---------------------|---|-----|--------|------------------------|
| 1 m                 | 1 | 0.43| 0.18, 0.99 | —                     |
| 3 m                 | 3 | 0.77| 0.54, 1.10 | 0%                     |
| 6 m                 | 3 | 0.99| 0.77, 1.28 | 56%                    |

| Administration      | N | RR  | 95% CI | Heterogeneity test (I²) |
|---------------------|---|-----|--------|------------------------|
| Intravenously       | 4 | 0.90| 0.67, 1.22 | 63%                    |
| Intramuscularly     | 2 | 0.67| 0.37, 1.19 | 0%                     |
| Orally              | 1 | 0.71| 0.39, 1.27 | —                     |

Figure 3. The efficacy of progesterone in improving outcomes (good recovery) in comparison with placebo. (A) acute traumatic brain injury; (B) acute severe traumatic brain injury.
proven to reduce mortality significantly at the confirmatory stage\textsuperscript{24–27}. The trauma of individual patients could not be controlled well in comparison with the animal model. The heterogeneity and variability of TBI may be one of the important reasons\textsuperscript{14,28}. This classification scheme of patients may be relatively insensitive using the Glasgow Coma Scale (GCS) or the Glasgow Outcome Scale-Extended (GOSE)\textsuperscript{28,29}.

Some limitations must be noted in this present study. First, one included study excluded female patients as a result of side effects on the menstrual cycle\textsuperscript{12}. Second, due to the lack of available data, we did not analyze other clinical outcomes except mortality and good recovery. It was unknown whether progesterone promoted the recovery of motor and sensory skills. Finally, the follow-up was short-term and varied across the studies. Thus, an appropriate dosage and a long-term follow-up may be necessary to further investigate the efficacy of progesterone in the treatment of acute TBI.

In conclusion, the pooled data did not support the idea that progesterone was superior to placebo in the treatment of acute TBI. Progesterone may be not effective in lowering the incidence of death or vegetative state in patients with acute TBI.

### Methods

#### Search strategy.

Our electronic search was conducted in PubMed, Embase, and the Cochrane Library databases until May 10, 2015. The core terms included “progesterone” and “head injury,” “traumatic brain injury,” “TBI,” “random,” and “random*”. There was no language limitation. We also searched Google Scholar and checked the reference lists of the included studies to identify any additional eligible articles.

#### Inclusion criteria.

Studies were included if they met the following criteria: (1) adults (older than 18 years) with a diagnosis of acute TBI, (2) progesterone compared with placebo (or no progesterone), and (3) randomized controlled trials. Duplicate articles, reviews, case reports, and studies without extractable data were excluded.

#### Data extraction and outcome measures.

Two authors (CL and HQH) independently extracted the following data from each included study in the standard form: (1) study characteristics (author’s name, date of publication, study design, sample size), (2) characteristics of participants (age and gender), (3) interventions (administration, duration, and dosage), and (4) outcomes (GOS and adverse events). Any discrepancies were discussed and resolved by the research team when necessary. The efficacy outcome was assessed with death or vegetative state (GOS = 1 or 2) and good recovery (GOS = 5) at the 6 months after TBI or end of the follow-up period. Adverse events included pneumonia and sepsis.

#### Quality assessment.

The eligible studies were evaluated according to the Cochrane Collaboration’s tool\textsuperscript{30}. The domains were as follow: selection bias (random method and allocation concealment), performance and detection bias (blinding of participants, personnel and outcome assessment), attrition bias (incomplete outcome data), and reporting bias (selective reporting).

#### Statistical analysis.

The data were analyzed with the Cochrane Review Manager 5.3 and STATA 11.0 software according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement\textsuperscript{31,32}. Risk ratios (RR) were calculated and pooled with a 95% confidence interval (CI) for dichotomous variables. The heterogeneity was estimated using the $I^2$ test, which was considered to be low heterogeneity when $I^2 \leq 25\%$. A fixed-effects random effects model was used if the $I^2$ was $\leq 25\%$. 

---

**Figure 4. Safety of progesterone in the treatment of traumatic brain injury.** (A) pneumonia; (B) sepsis.
Otherwise, a random effects model was applied. We used the funnel plot and Eger's test to assess potential publication bias.

**References**

1. Ghajar, J. Traumatic brain injury. *Lancet* **356**, 923–929 (2000).
2. Maas, A. I., Stocchetti, N. & Bullock, R. Moderate and severe traumatic brain injury in adults. *Lancet Neurol* **7**, 728–741 (2008).
3. Coronado, V. G. et al. Trends in Traumatic Brain Injury in the U.S. and the public health response: 1995–2009. *J Safety Res** **43**, 299–307 (2012).
4. Langlois, J. A., Rutland-Brown, W. & Wald, M. M. The epidemiology and impact of traumatic brain injury: a brief overview. *J Head Trauma Rehabil* **21**, 375–378 (2006).
5. Stein, D. G., Wright, D. W. & Kellermann, A. L. Does progesterone have neuroprotective properties. *Ann Emerg Med* **51**, 164–172 (2008).
6. Pascual, J. L. et al. Neuroprotective effects of progesterone in traumatic brain injury: blunted in vivo neutrophil activation at the blood-brain barrier. *Ann J Surg* **206**, 840–845 (2013).
7. Si, D. et al. Progesterone treatment improves cognitive outcome following experimental traumatic brain injury in rats. *Neurosci Lett* **553**, 18–23 (2013).
8. Xiao, G., Wei, J., Yan, W., Wang, W. & Lu, Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. *Crit Care* **12**, R61 (2008).
9. Skolnick, B. E. et al. A clinical trial of progesterone for severe traumatic brain injury. *N Engl J Med* **371**, 2467–2476 (2014).
10. Xiao, G. M. et al. [Clinical study on the therapeutic effects and mechanism of progesterone in the treatment for acute severe head injury]. *Zhonghua Wai Ke Za Zhi* **45**, 106–108 (2007).
11. Aminmansour, B. et al. Comparison of the administration of progesterone versus progesterone and vitamin D in improvement of outcomes in patients with traumatic brain injury: A randomized clinical trial with placebo group. *Adv Biomed Res* **1**, 58 (2012).
12. Shafer, M. et al. Effect of progesterone administration on prognosis of patients with diffuse axonal injury due to severe head trauma. *Clin Neurol Neurosurg* **115**, 2019–2022 (2013).
13. Wright, D. W. et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. *Ann Emerg Med* **49**, 391–402 (2007).
14. Wright, D. W. et al. Very early administration of progesterone for acute traumatic brain injury. *N Engl J Med* **371**, 2457–2466 (2014).
15. Maas, A. I., Stocchetti, N. & Bullock, R. Moderate and severe traumatic brain injury in adults. *Lancet Neurol* **7**, 728–741 (2008).
16. Mustafa, A. G. & Alshboul, O. A. Pathophysiology of traumatic brain injury. *Neurosciences (Riyadh)* **18**, 222–234 (2013).
17. Park, E., Bell, J. D. & Baker A. J. Traumatic brain injury: can the consequences be stopped? *CMAJ* **178**, 1163–1170 (2008).
18. Margulies, S. & Hicks, R. Combination therapies for traumatic brain injury: prospective considerations. *J Neurotrauma* **26**, 925–939 (2009).
19. Drew, P. D. & Chavis, J. A. Female sex steroids: effects upon microglial cell activation. *J Neuroimmunol* **111**, 77–85 (2000).
20. He, J., Hoffman, S. W. & Stein, D. G. Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. *Restor Neurol Neurosci* **22**, 19–31 (2004).
21. Cutler, S. M. et al. Progesterone improves acute recovery after traumatic brain injury in the aged rat. *J Neurotrauma* **24**, 1475–1486 (2007).
22. Li, Z. et al. Progesterone increases circulating endothelial progenitor cells and induces neural regeneration after traumatic brain injury in aged rats. *J Neurotrauma* **29**, 343–353 (2012).
23. Ma, J., Huang, S., Qin, S. & You, C. Progesterone for acute traumatic brain injury. *Cochrane Database Syst Rev* **10**, CD008409 (2012).
24. Narayan, R. K. et al. Clinical trials in head injury. *J Neurotrauma* **19**, 503–557 (2002).
25. Schouten, J. W. Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature. *Curr Opin Crit Care* **13**, 134–142 (2007).
26. Loane, D. J. & Faden, A. I. Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. *Trends Pharmacol Sci* **31**, 596–604 (2010).
27. Maas, A. I., Roosenbeek, B. & Manley, G. T. Clinical trials in traumatic brain injury: past experience and current developments. *Neurotherapeutics* **7**, 115–126 (2010).
28. Manley, G. T. & Maas, A. I. Traumatic brain injury: an international knowledge-based approach. *JAMA* **310**, 473–474 (2013).
29. Wilson, J. T., Pettigrew, L. E. & Teasdale, G. M. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. *J Neurotrauma* **15**, 573–585 (1998).
30. Higgins, J. P. et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* **334**, d5928 (2011).
31. Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* **151**, W65–94 (2009).
32. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* **6**, e1000097 (2009).
33. Egger, M., Davey, S. G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* **315**, 629–634 (1997).

**Acknowledgments**

This study was supported by grants from the National Natural Science Foundation of China (No. 81471269 (BA14)).

**Author Contributions**

C.L. and H.-H.Q. designed the experiments. C.L. and Z.L. performed the experiments. C.-H.L. analyzed the data. C.L. and J.J. wrote the manuscript. Critical revision, final drafting and text approval were performed by L.-Y.L., C.L. and N.L.

**Additional Information**

**Competing financial interests**: The authors declare no competing financial interests.

**How to cite this article**: Lin, C. *et al*. Efficacy of progesterone for moderate to severe traumatic brain injury: a meta-analysis of randomized clinical trials. *Sci. Rep.* **5**, 13442; doi: 10.1038/srep13442 (2015).
